SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight ($NIGHT) is generating significant community conversation as traders weigh the platform's focus on privacy-enhancing ZK proofs against concerns regarding its decentralization and high-profile partnerships. While some supporters highlight its potential within the Cardano ecosystem and its recent network milestones, others are actively debating its valuation, the impact of token airdrops on market stability, and ongoing legal scrutiny involving the project's early NFT initiatives.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors digest a mix of financial results and strategic positioning, with the community closely tracking the company's deepening integration into AI infrastructure and optical networking. While short-term volatility and mixed analyst outlooks drive debate, long-term investors are highlighting Nokia's role in next-generation connectivity as a key tailwind for the stock.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF (SHLD) is trending as investors capitalize on surging global military spending and geopolitical instability, with the community highlighting its strategic exposure to both U.S. giants and international defense leaders. Traders are closely monitoring the ETF's resilience and its concentrated positions in high-growth AI and defense-tech names as a play on long-term sector tailwinds.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing significant volatility as the community remains sharply divided, fueled by intense speculation regarding its integration with OpenAI and ongoing institutional accumulation by players like Eightco Holdings. While some investors view the biometric proof-of-personhood technology as a necessary pillar for the AI-driven internet, others are heavily criticizing its tokenomics and recent price performance, creating a highly polarized atmosphere ahead of upcoming roadmap milestones.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as investors focus on a pivotal period of growth, driven by expectations of a strong Vevye sales ramp following its move to preferred formulary status at CVS. Community discussions highlight high conviction in the stock's long-term potential, with many focusing on the company's expanding sales force and upcoming product launches as key catalysts for a significant revaluation in the coming quarters.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as investors digest a major merger agreement with Valaris alongside a positive earnings report that highlighted significant debt reduction and record fleet uptime. The community remains focused on the company's long-term offshore drilling turnaround, with many traders actively discussing potential price targets and the impact of these strategic shifts on future valuation.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

The Grayscale Bitcoin Trust (GBTC) is currently a focal point of intense debate as investors weigh concerns over elevated management fees against its role as a proxy for broader Bitcoin price action. Market participants are actively scrutinizing the impact of institutional outflows and macroeconomic headwinds, while long-term bulls remain focused on the potential for institutional accumulation and BTC price recovery.

Investment Managers Series Trust II - Tradr 2X Short TSLA Daily ETF

Tradr 2X Short TSLA Daily ETF

TSLQ is currently trending as traders aggressively debate Tesla's valuation, with many community members using the inverse ETF to bet against the stock's recent volatility and technical performance. The conversation is driven by intense focus on Tesla's leadership, upcoming earnings, and the broader debate over whether the stock is a long-term growth play or a heavily manipulated retail trap.

Fidelity Wise Origin Bitcoin Fund - Fidelity Wise Origin Bitcoin Fund Beneficial Interest

Fidelity Wise Origin Bitcoin Fund

Fidelity Wise Origin Bitcoin Fund (FBTC) is seeing intense community engagement as investors debate its role as a strategic proxy for Bitcoin during a period of extreme market volatility and geopolitical uncertainty. The conversation is dominated by discussions on the fund's utility for tax-advantaged retirement accounts, the potential impact of long-term institutional accumulation, and the broader debate between holding spot assets in cold storage versus utilizing regulated ETFs.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is currently trending as investors debate whether a potential diplomatic meeting between U.S. and Chinese leadership will stabilize the outlook for Chinese ADRs and trigger a rally in the stock. The community is actively discussing the stock's strong fundamental growth against the backdrop of broader market volatility, with many pointing to its shift toward non-mainland clients as a key point of divergence from its current market valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Surge In Jaguar Health Stock: What's Happening Now?

Jaguar Health Inc (NASDAQ:JAGX) subsidiary, Napo Pharmaceuticals, has struck a new licensing deal with Woodward Specialty.read more...

June 26, 2025<a target="_blank" rel="noopener noreferrer nofollow" href="https://jaguarhealth.gcs-web.com/node/15251/pdf">PDF Version</a>Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of valueSAN FRANCISCO, CA / <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/">ACCESS Newswire</a> / June 26, 2025 / <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue6">Jaguar Health, Inc.</a> (<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue7">NASDAQ:JAGX</a>) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset."Cryptocurrencies continue to gain investor attention and acceptance as a major asset class. We believe selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, diversifying our assets to include a digital store of value that we believe has significant upside potential and may also provide a safeguard against inflation," said Lisa Conte, Jaguar's Founder and CEO. "Jaguar has been approached by several banks and an investor with terms for cryptocurrency transactions. The Company is assessing the potential value to shareholders, and the potential benefits for our core development programs, of making selected cryptocurrencies a treasury reserve asset for the Company."Jaguar's has three core development programs for crofelemer, the Company's novel plant-based prescription medicine: its orphan disease intestinal failure program; its ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and its ongoing development program to expand access for <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue8">Canalevia</a>® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea. Each of these core programs for crofelemer is the subject of business development goals of forging corporate partnerships to bring in non-dilutive funding for the Company.About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bue9">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.For more information about:Jaguar Health, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buea">https://jaguar.health</a>Napo Pharmaceuticals, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueb">www.napopharma.com</a>Napo Therapeutics, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buec">napotherapeutics.com</a>Magdalena Biosciences, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bued">magdalenabiosciences.com</a>Canalevia-CA1, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buee">canalevia.com</a>Visit the Make Cancer Less Shitty patient advocacy program on <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buef">Bluesky</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueg">X</a>, <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/bueh">Facebook</a> &amp; <a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/buei">Instagram</a>Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements." These include statements regarding making selected cryptocurrencies a treasury reserve asset for the Company, Jaguar's belief that selected cryptocurrencies could serve as a strong treasury reserve asset for the Company, Jaguar's belief that there may be significant upside potential in diversifying the Company's assets to include a digital store of value, Jaguar's belief that diversifying the Company's assets to include a digital store of value may provide a safeguard against inflation, the potential value to shareholders of making selected cryptocurrencies a treasury reserve asset for the Company, and the potential benefits for Jaguar's core development programs of making selected cryptocurrencies a treasury reserve asset for the Company.In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.CONTACT: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a> Jaguar-JAGXSOURCE:&nbsp;Jaguar Health, Inc. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/jaguar-health-board-of-directors-authorizes-company-to-include-crypto-1043232">press release</a>

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Others

Investor retail chatter spiked for Jaguar Health Inc. on Wednesday after the company revealed its plan for a $1.5 million registered direct offering priced at-the-market under Nasdaq rules.Jaguar Health shares fell 27.05% to close at $4.26 on Wednesday, before recovering 3.99% in after-hours trading to $4.43.The biopharmaceutical company finalized agreements to exchange 246,306 shares of common stock for $6.09 per share.&nbsp;Jaguar will distribute unregistered warrants in a simultaneous private placement. The exercise price is $5.84 per share, and purchasers can buy up to 492,612 shares.&nbsp;These warrants become exercisable immediately and expire after a fundamental transaction or liquidation event occurs or after 24 months, whichever condition is first met.The offering's closure is scheduled for May 22, subject to standard conditions. H.C. Wainwright &amp; Co. holds exclusive placement agency responsibilities.Jaguar plans to use net proceeds to finance general corporate purposes, such as growth capital funding, working capital maintenance, convertible note repayment, and capital expenditure needs.On Stocktwits, retail sentiment was ‘bullish’ amid a 444% surge in 24-hour message volume.Some retail traders described the offering as a “dip opportunity,” pointing to prior disclosures about share sales through the at-the-market program and suggesting the move had been anticipated since 2022.&nbsp;<stembedurl>https://stocktwits.com/jimiinfinity/message/615411703</stembedurl>Others framed the discounted pricing as a potential entry point, expressing optimism about upcoming news and the company’s trajectory.<stembedurl>https://stocktwits.com/Torobravo_1/message/615384587</stembedurl>The stock has declined 84.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jaguar Health $1.5M Stock Offering Sparks Retail Buzz; Traders Call It A ‘Dip Opportunity’

Jaguar Health is raising $1.5 million through a registered direct offering and concurrent private warrants placement to support general corporate and growth initiatives.

Equity

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

This account has been verified as an official JAGX representative.

Verified Account

Jagaur Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Jaguar Health Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$0.3427
Prev Close	$0.3923
Open	$0.39
Dividend Yield	0.00%
50-Day Moving Average	$0.6312
Beta	2.00
Avg. Volume	411,708.70
PE Ratio	-0.01

52-Week High	$15.48
52-Week Low	$0.3427
Market Capitalization	$1.28M
EPS (Annual)	-$5.23
Price to Book	0.40
Revenue Per Employee	$238,551.02

JAGX
Jaguar Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JAGX News

JAGXJaguar Health Inc